JP2004532885A5 - - Google Patents

Download PDF

Info

Publication number
JP2004532885A5
JP2004532885A5 JP2003501497A JP2003501497A JP2004532885A5 JP 2004532885 A5 JP2004532885 A5 JP 2004532885A5 JP 2003501497 A JP2003501497 A JP 2003501497A JP 2003501497 A JP2003501497 A JP 2003501497A JP 2004532885 A5 JP2004532885 A5 JP 2004532885A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antibody
mammal
eye
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003501497A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004532885A (ja
Filing date
Publication date
Priority claimed from US09/894,287 external-priority patent/US6534059B2/en
Application filed filed Critical
Publication of JP2004532885A publication Critical patent/JP2004532885A/ja
Publication of JP2004532885A5 publication Critical patent/JP2004532885A5/ja
Pending legal-status Critical Current

Links

JP2003501497A 2001-06-05 2002-06-04 眼内の過免疫応答を処置するための組成物および方法 Pending JP2004532885A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29589501P 2001-06-05 2001-06-05
US09/894,287 US6534059B2 (en) 2001-06-05 2001-06-28 Compositions and methods for treating hyperimmune response in the eye
PCT/US2002/017677 WO2002098460A1 (en) 2001-06-05 2002-06-04 Compositions and methods for treating hyperimmune response in the eye

Publications (2)

Publication Number Publication Date
JP2004532885A JP2004532885A (ja) 2004-10-28
JP2004532885A5 true JP2004532885A5 (https=) 2006-01-05

Family

ID=26969391

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003501497A Pending JP2004532885A (ja) 2001-06-05 2002-06-04 眼内の過免疫応答を処置するための組成物および方法

Country Status (8)

Country Link
US (2) US6534059B2 (https=)
EP (1) EP1401496B1 (https=)
JP (1) JP2004532885A (https=)
AT (1) ATE343398T1 (https=)
AU (1) AU2002318175B2 (https=)
CA (1) CA2449488C (https=)
DE (1) DE60215649D1 (https=)
WO (1) WO2002098460A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6709655B2 (en) * 2001-02-28 2004-03-23 Instituto Bioclon, S.A. De C.V. Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof
US6861056B2 (en) * 2001-06-05 2005-03-01 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US6534059B2 (en) * 2001-06-05 2003-03-18 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US6712976B2 (en) * 2001-09-13 2004-03-30 Abtech Industries, Inc. Dual-action decontamination system
US7335759B2 (en) 2002-12-02 2008-02-26 Universidad Nacional Autónoma de Méxica (UNAM) Recombinant immunogens for the generation of antivenoms to the venom of scorpions of the genus Centruroides
EP1651266B1 (en) * 2003-07-25 2010-03-03 Laboratorios Silanes, S.A. de C.V. Administration of anti-tnf-alpha f(ab')2 antibody fragments
PT1848744E (pt) 2005-01-27 2012-04-24 Novimmune Sa Anticorpos anti-interferão gama e os seus processos de utilização
US20100003264A1 (en) * 2005-03-24 2010-01-07 Washington University Reduction of Ophthalmalogic Neovascularization
US7381802B2 (en) * 2005-04-15 2008-06-03 Universidad Nacional Autónoma De México (UNAM) Human antibodies that specifically recognize the toxin Cn2 from Centruroides noxius scorpion venom
CA2654565A1 (en) * 2006-06-12 2007-12-21 Therakine Limited Topical treatment for diseases of eye surface
EP2326342B1 (en) 2008-08-15 2021-10-06 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using interferon gamma to absorb fluid from the subretinal space
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
CN121588213A (zh) 2015-05-07 2026-03-03 瑞典孤儿比奥维特鲁姆股份公司 用于诊断和治疗cxcl9和其它生物标志物水平升高的患者的病症

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
UA41863C2 (uk) 1985-10-25 2001-10-15 Займодженетікс Інк. Спосіб одержання гетерологічного поліпептиду в еукаріотичних мікроорганізмах
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905400D0 (en) * 1989-03-09 1989-04-19 Jonker Margreet Medicaments
DE69229275T2 (de) * 1991-10-04 1999-12-30 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Rockville Herstellung eines arzneimittels zur behandlung von augenentzündung durch blockierung von zelladhäsionsmolekulen
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
DE19535073C1 (de) * 1995-09-21 1997-02-20 Roland Dr Grosmann Verfahren zur künstlichen Inkubation von Hühnereiern
US6861056B2 (en) * 2001-06-05 2005-03-01 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US6534059B2 (en) * 2001-06-05 2003-03-18 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye

Similar Documents

Publication Publication Date Title
JP2004532885A5 (https=)
JP2009507838A5 (https=)
WO2009039992A3 (en) Use of band 3 protein (824-829) and/or melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection
HUE045639T2 (hu) Pan-KIR2DL NK-receptor antitestek és felhasználásuk diagnosztikában és terápiában
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
JP2013501814A5 (https=)
ZA200609407B (en) Monoclonal antibodies to hepatocyte growth factor
RU2015110635A (ru) Лечение сосудистого заболевания и его осложнений
CA2449488A1 (en) Compositions and methods for treating hyperimmune response in the eye
NZ542866A (en) Compositions and methods for the therapy of inflammatory bowel disease
ATE194497T1 (de) Monoklonale antikoerper gegen lfa-1 zur herstellung eines arzneimittels zur vorbeugung der transplantatabstossung von organen
WO2004106378A3 (en) Method of treating corneal transplant rejection by using vegf antagonists
RU2013137645A (ru) Аналоги цистамина, применяемые для лечения болезни паркинсона
DE60313356D1 (de) Verwendungvon dextransulfat zur behandlung von ibmir
NO20055187L (no) Fremgangsmate for behandling og forebygging av lavere urinkanal symptomer
DE69727691D1 (de) Verwendung von keratinocyten-wachstumsfaktor-2
MXPA02006511A (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido.
Robson et al. Acute management of the burned patient
WO2024112527A3 (en) Methods for the treatment of thyroid eye disease
JP2000178203A5 (https=)
Cantor et al. Comparison of the clinical success and quality-of-life impact of brimonidine 0.2% and betaxolol 0.25% suspension in patients with elevated intraocular pressure
Ozcan et al. Symblepharon ring-amniotic membrane application in persistent corneal epithelial defect
Ghosh Cutaneous manifestations of systemic lupus erythematosus
EA200300430A1 (ru) Новые фармацевтические композиции, содержащие эпинастин и псевдоэфедрин